US · Healthcare · Biotechnology
EPS came in at -0.06 against a street estimate of -0.02 — a miss of 200.0%.
Analysts rate MannKind Corp a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $7.97.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.89% |
| State Street Corp | 5.81% |
| Vanguard Capital Management, LLC | 4.01% |
| UBS Group AG | 2.57% |
| Wellington Management Company LLP | 2.44% |
| Geode Capital Management, LLC | 2.33% |
| Deep Track Capital, LP | 1.87% |
| Frazier Life Sciences Management, L.P. | 1.83% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 MANNKIND CORPORATION (MNKD) - 8-K FILING SUMMARY HEADLINE NUMBERS • Filing Date: August 21, 2026 • Company: MannKind Corporation, Delaware incorpora | 2026-08-21 |
| Quarterly report · Q2 2026 MANNKIND CORPORATION – 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total revenues (6 months ended June 30, 2026): $199.5 million vs. $154.9 | 2026-08-05 |
| Results announced · Q3 2026 MANNKIND CORPORATION – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 total revenues: $109.4 million, up 43% vs. Q2 2025 ($76.5 million) • H1 | 2026-08-05 |
| Company announcement · Q3 2026 MANNKIND CORPORATION – 8-K SUMMARY HEADLINE NUMBERS • Capital Raised: $50.0 million gross proceeds from private placement (July 24, 2026) • Shares I | 2026-07-24 |
| Company announcement · Q2 2026 MANNKIND CORPORATION - 8-K SUMMARY HEADLINE NUMBERS • FDA approval announced May 29, 2026 for Afrezza (insulin human) Inhalation Powder in pediatric | 2026-06-02 |
| Quarterly report · Q1 2026 MANNKIND CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue Q1 2026: $90.2 million (up 15% vs. $78.4 million in Q1 2025) • Net Loss | 2026-05-06 |
| Proxy statement · Q2 2026 MANNKIND CORPORATION – PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine directors for one-year terms ending at the 2 | 2026-04-07 |
| Annual report FY2025 MANNKIND CORPORATION – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization: Approximately $1.13 billion as of June 30, 2025 • | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for MannKind Corp — free to start.
Google PlayApp StoreData updated 2026-09-18.